[1]阮莹莹 闫彩凤.GLP-1对2型糖尿病患者骨骼的影响[J].国际内分泌代谢杂志,2018,38(04):275-278.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
 Ruan Yingying,Yan Caifeng..The impact of GLP-1 on bone in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(04):275-278.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
点击复制

GLP-1对2型糖尿病患者骨骼的影响()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
38
期数:
2018年04期
页码:
275-278
栏目:
基础研究
出版日期:
2018-07-20

文章信息/Info

Title:
The impact of GLP-1 on bone in patients with type 2 diabetes
作者:
阮莹莹 闫彩凤
116044 大连医科大学研究生院(阮莹莹); 225001 扬州,江苏省苏北人民医院内分泌科(阮莹莹、闫彩凤)
Author(s):
Ruan Yingying Yan Caifeng.
Graduate School, Dalian Medical University, Dalian 116044, China; Department of Endocrinology, Subei People's Hospital of Jiangsu Province, Yangzhou 225001, China
关键词:
胰高血糖素样肽-1 2型糖尿病 骨形成 骨吸收 骨折
Keywords:
Glucagon-like peptide-1 Type 2 diabetes mellitus Bone formation Bone resorption Fracture
DOI:
10.3760/cma.j.issn.1673-4157.2018.04.014
摘要:
2型糖尿病患者骨折风险升高,因此在降糖治疗的同时关注降糖药物对骨骼的影响具有重要意义。研究发现,胰高血糖素样肽-1(GLP-1)类药物不仅能够控制血糖,还能通过调节成骨细胞Wnt通路、促进骨髓间充质干细胞向成骨细胞分化、影响破骨细胞核因子-κB受体活化因子配体通路、抑制骨细胞分泌骨硬化蛋白以及其他途径改善骨代谢,提示这类药物对2型糖尿病患者骨质疏松的防治有重要作用。
Abstract:
The risk of fractures in patients with type 2 diabetes is increased, therefore, it is important to take into account the effects of anti-diabetic therapies on bone. Studies show that glucagon-like peptide-1(GLP-1)-based therapies not only can lower blood glucose, but also improve bone metabolism by regulating Wnt pathways in osteoblast,promoting osteogenic differentiation of bone marrow mesenchymal stem cell(BMSC),regulating receptor activator of nuclear factor κB ligand pathways in osteoclast, inhibiting sclerostin secretion of osteocyte, etc. It suggests that GLP-1-based therapies play an essential role in the prevention and treatment of osteoporosis in patients with type 2 diabetes.

参考文献/References:


[1] Moayeri A,Mohamadpour M,Mousavi SF,et al.Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis[J].Ther Clin Risk Manag,2017,13:455-468.DOI:10.2147/TCRM.S131945.
[2] Cantini G,Mannucci E,Luconi M.Perspectives in GLP-1 research: new targets, new receptors[J].Trends Endocrinol Metab,2016,27(6):427-438.DOI:10.1016/j.tem.2016.03.017.
[3] Nauck M.Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors[J].Diabetes Obes Metab,2016,18(3):203-216.DOI:10.1111/dom.12591.
[4] Nuche-Berenguer B,Portal-Núnez S,Moreno P,et al.Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor[J].J Cell Physiol,2010,225(2):585-592.DOI:10.1002/jcp.22243.
[5] Ma X,Meng J,Jia M,et al.Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats[J].J Bone Miner Res,2013,28(7):1641-1652.DOI:10.1002/jbmr.1898.
[6] Sun HX,Lu N,Luo X,et al. Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats[J].J Diabetes,2015,7(4):584-588.DOI:10.1111/1753-0407.12282.
[7] Nuche-Berenguer B,Moreno P,Portal-Núnez S,et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states[J].Regul Pept,2010,159(1-3):61-66.DOI:10.1016/j.regpep.2009.06.010.
[8] Hygum K,Starup-Linde J,Harsløf T,et al. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover-a systematic review and meta-analysis[J].Eur J Endocrinol,2017,176(3):R137-R157.DOI:10.1530/EJE-16-0652.
[9] Kim JY,Lee SK,Jo KJ,et al.Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes[J].Life Sci,2013,92(10):533-540.DOI:10.1016/j.lfs.2013.01.001.
[10] Pereira M,Jeyabalan J,Jørgensen CS,et al. Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice[J].Bone,2015,81:459-467.DOI:10.1016/j.bone.2015.08.006.
[11] Eom YS,Gwon AR,Kwak KM,et al.Protective effects of vildagliptin against pioglitazone-induced bone loss in type 2 diabetic rats[J].PLoS One,2016,11(12):e0168569.DOI:10.1371/journal.pone.0168569.
[12] Meng J, Ma X, Wang N,et al. Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through β-catenin[J]. Stem Cell Reports,2016,6(4):579-591.DOI:10.1016/j.stemcr.2016.02.002.
[13] Sanz C,Vázquez P,Blázquez C,et al. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow[J].Am J Physiol Endocrinol Metab,2010,298(3):E634-E643. DOI:10.1152/ajpendo.00460.2009.
[14] Lee HM,Joo BS,Lee CH,et al.Effect of glucagon-like peptide-1 on the differentiation of adipose-derived stem cells into osteoblasts and adipocytes[J].J Menopausal Med,2015,21(2):93-103.DOI:10.6118/jmm.2015.21.2.93.
[15] Yamagishi S.Comment on:Monami et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials[J]. Diabetes Care 2011; 34:2474-2476[J].Diabetes Care,2012,35(4):e33.DOI:10.2337/dc11-2561.
[16] Yamada C,Yamada Y,Tsukiyama K,et al.The murine glucagon-like peptide-1 receptor is essential for control of bone resorption[J].Endocrinology,2008,149(2):574-579.DOI:10.1210/en.2007-1292.
[17] Gier B,Butler PC,Lai CK,et al.Glucagon like peptide-1 receptor expression in the human thyroid gland[J].J Clin Endocrinol Metab,2012,97(1):121-131.DOI:10.1210/jc.2011-2407.
[18] Waser B,Blank A,Karamitopoulou E,et al.Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas[J].Mod Pathol,2015,28(3):391-402.DOI:10.1038/modpathol.2014.113.
[19] Nuche-Berenguer B,Moreno P,Esbrit P,et al.Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states[J].Calcif Tissue Int,2009,84(6):453-461.DOI:10.1007/s00223-009-9220-3.
[20] Nuche-Berenguer B,Lozano D,Gutiérrez-Rojas I,et al.GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia[J].J Endocrinol,2011,209(2):203-210.DOI:10.1530/JOE-11-0015.
[21] Mieczkowska A,Mansur S,Bouvard B,et al.Double incretin receptor knock-out(DIRKO)mice present with alterations of trabecular and cortical micromorphology and bone strength[J].Osteoporos Int,2015,26(1):209-218.DOI:10.1007/s00198-014-2845-8.
[22] Su B,Sheng H,Zhang M,et al.Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials[J].Endocrine,2015,48(1):107-115.DOI:10.1007/s12020-014-0361-4.
[23] Mabilleau G,Mieczkowska A,Chappard D.Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials[J].J Diabetes,2014,6(3):260-266.DOI:10.1111/1753-0407.12102.
[24] Dombrowski S,Kostev K,Jacob L.Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data[J].Osteoporos Int,2017,28(8):2421-2428.DOI:10.1007/s00198-017-4051-y.
[25] Monami M,Dicembrini I,Antenore A,et al.Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials[J].Diabetes Care,2011,34(11):2474-2476.DOI:10.2337/dc11-1099.
[26] Fu J,Zhu J,Hao Y,et al. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials[J].Sci Rep,2016,6:29104.DOI:10.1038/srep29104.DOI:10.1038/srep29104.
[27] Mamza J,Marlin C,Wang C,et al.DPP-4 inhibitor therapy and bone fractures in people with type 2 diabetes-a systematic review and meta-analysis[J].Diabetes Res Clin Pract,2016,116:288-298.DOI:10.1016/j.diabres.2016.04.029.
[28] Li R,Xu W,Luo S,et al.Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes[J].Acta Diabetol,2015,52(6):1083-1091.DOI:10.1007/s00592-015-0792-2.

相似文献/References:

[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
 Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(04):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
 Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(04):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
 Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[4]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
 Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(04):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[5]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
 Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(04):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[6]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
 Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[7]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
 Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(04):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[8]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性 血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
 Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(04):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[9]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白 与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
 Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(04):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[10]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平 及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
 Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[11]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
 Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(04):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[12]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
 Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(04):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
[13]史雨清,杨昱,李宸,等.Tirzepatide:一种新型GLP-1/GIP双受体激动剂[J].国际内分泌代谢杂志,2021,41(06):645.[doi:10.3760/cma.j.cn121383-20200924-09046]
 Shi Yuqing,Yang Yu,Li Chen,et al.Tirzepatide:a novel GLP-1/GIP dual receptor agonist[J].International Journal of Endocrinology and Metabolism,2021,41(04):645.[doi:10.3760/cma.j.cn121383-20200924-09046]

备注/Memo

备注/Memo:
基金项目:扬州市社会发展基金(YZ2016061)
通信作者:闫彩凤,Email: yancaifeng@126.com
更新日期/Last Update: 2018-04-30